MX2023010241A - Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos. - Google Patents
Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos.Info
- Publication number
- MX2023010241A MX2023010241A MX2023010241A MX2023010241A MX2023010241A MX 2023010241 A MX2023010241 A MX 2023010241A MX 2023010241 A MX2023010241 A MX 2023010241A MX 2023010241 A MX2023010241 A MX 2023010241A MX 2023010241 A MX2023010241 A MX 2023010241A
- Authority
- MX
- Mexico
- Prior art keywords
- triazolyl
- methyl substituted
- substituted alpha
- galactopyranoside
- derivatives
- Prior art date
Links
- 102000000802 Galectin 3 Human genes 0.000 abstract 1
- 108010001517 Galectin 3 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención se refiere a los compuestos de la Fórmula (I). (ver Fórmula) Fórmula (I) en donde A, R1, R2, RP2, RP3 y RP4 son como se describe en la descripción, su preparación, a sales farmacéuticamente aceptables de los mismos, y a su uso como farmacéuticos, a composiciones farmacéuticas que contienen uno o más compuestos de la fórmula (I), y especialmente a su uso como inhibidores de Galectina-3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021055348 | 2021-03-03 | ||
| PCT/EP2022/055224 WO2022184755A1 (en) | 2021-03-03 | 2022-03-02 | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010241A true MX2023010241A (es) | 2023-09-12 |
Family
ID=80682779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010241A MX2023010241A (es) | 2021-03-03 | 2022-03-02 | Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240109930A1 (es) |
| EP (1) | EP4301748A1 (es) |
| JP (1) | JP2024509421A (es) |
| KR (1) | KR20230154221A (es) |
| CN (1) | CN116888113A (es) |
| AU (1) | AU2022228660A1 (es) |
| BR (1) | BR112023017624A2 (es) |
| CA (1) | CA3209917A1 (es) |
| CL (1) | CL2023002578A1 (es) |
| IL (1) | IL305581A (es) |
| MX (1) | MX2023010241A (es) |
| TW (1) | TW202300146A (es) |
| WO (1) | WO2022184755A1 (es) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| CA2926917C (en) | 2012-10-10 | 2021-01-05 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
| IN2015DN02573A (es) | 2012-10-31 | 2015-09-11 | Galecto Biotech Ab | |
| JP6366598B2 (ja) | 2012-11-15 | 2018-08-01 | タフツ ユニバーシティー | ガレクチンタンパク質阻害剤を用いて被験体の眼の血管新生または繊維症を処置し、調節し、または、予防する方法、組成物、およびキット |
| EP3250581B1 (en) | 2015-01-30 | 2021-01-20 | Galecto Biotech AB | Alpha-d-galactoside inhibitors of galectins |
| IL293770B2 (en) | 2015-07-06 | 2023-07-01 | Gilead Sciences Inc | Modulators of cot and methods of using them |
| JP2020519597A (ja) | 2017-05-12 | 2020-07-02 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 全身性インスリン抵抗性障害の治療用化合物およびその使用 |
| AU2018265571B2 (en) | 2017-05-12 | 2022-09-29 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| US11267811B2 (en) | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| US11072626B2 (en) | 2017-10-11 | 2021-07-27 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| JP2021501180A (ja) | 2017-10-31 | 2021-01-14 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用 |
| US11447517B2 (en) | 2018-11-21 | 2022-09-20 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| US20220144818A1 (en) * | 2019-04-10 | 2022-05-12 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| US20230014870A1 (en) | 2019-07-03 | 2023-01-19 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| WO2021004940A1 (en) | 2019-07-05 | 2021-01-14 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| KR20220044785A (ko) | 2019-08-09 | 2022-04-11 | 이도르시아 파마슈티컬스 리미티드 | (헤테로)아릴-메틸-티오-베타-d-갈락토피라노시드 유도체 |
| ES2974680T3 (es) | 2019-08-09 | 2024-07-01 | Idorsia Pharmaceuticals Ltd | Derivados de (2-acetamidil)tio-beta-D-galactopiranósidos |
| KR20220047585A (ko) | 2019-08-15 | 2022-04-18 | 이도르시아 파마슈티컬스 리미티드 | 2-히드록시시클로알칸-1-카르바모일 유도체 |
| PL4021904T3 (pl) | 2019-08-29 | 2024-05-13 | Idorsia Pharmaceuticals Ltd | Pochodne alfa-d-galaktopiranozydu |
-
2022
- 2022-03-02 AU AU2022228660A patent/AU2022228660A1/en active Pending
- 2022-03-02 IL IL305581A patent/IL305581A/en unknown
- 2022-03-02 WO PCT/EP2022/055224 patent/WO2022184755A1/en active Application Filing
- 2022-03-02 KR KR1020237033375A patent/KR20230154221A/ko unknown
- 2022-03-02 MX MX2023010241A patent/MX2023010241A/es unknown
- 2022-03-02 EP EP22708569.3A patent/EP4301748A1/en active Pending
- 2022-03-02 TW TW111107565A patent/TW202300146A/zh unknown
- 2022-03-02 JP JP2023552539A patent/JP2024509421A/ja active Pending
- 2022-03-02 CA CA3209917A patent/CA3209917A1/en active Pending
- 2022-03-02 CN CN202280017484.3A patent/CN116888113A/zh active Pending
- 2022-03-02 US US18/548,833 patent/US20240109930A1/en active Pending
- 2022-03-02 BR BR112023017624A patent/BR112023017624A2/pt unknown
-
2023
- 2023-08-31 CL CL2023002578A patent/CL2023002578A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240109930A1 (en) | 2024-04-04 |
| BR112023017624A2 (pt) | 2023-10-10 |
| WO2022184755A1 (en) | 2022-09-09 |
| IL305581A (en) | 2023-10-01 |
| EP4301748A1 (en) | 2024-01-10 |
| AU2022228660A1 (en) | 2023-10-19 |
| TW202300146A (zh) | 2023-01-01 |
| CL2023002578A1 (es) | 2024-03-22 |
| JP2024509421A (ja) | 2024-03-01 |
| KR20230154221A (ko) | 2023-11-07 |
| CN116888113A (zh) | 2023-10-13 |
| CA3209917A1 (en) | 2022-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001379A (es) | Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a. | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| CL2023001461A1 (es) | Inhibidores de prmt5 novedosos | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
| MX2023001311A (es) | Agonistas heterociclicos de glp-1. | |
| CR20220371A (es) | Agonistas heterocíclicos de glp-1 | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| NO20090835L (no) | Nye HIV-reverstranskriptaseinhibitorer | |
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
| CR20220638A (es) | Derivados de amidopirimidona | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| SA520411787B1 (ar) | مشتقات بنزيميدازول واستخداماتها | |
| PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| MX2022007518A (es) | Derivados bencimidazol. | |
| CR20220538A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| SA522431777B1 (ar) | مشتقات ألفا -d- جالاكتو بيرانوسيد | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| MX2022016516A (es) | Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso. | |
| CR20230331A (es) | Derivados de pirazolamida | |
| MX2022013890A (es) | Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos. | |
| MX2023010241A (es) | Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos. | |
| MX2023009954A (es) | Compuestos de aminopirimidina y métodos de uso de estos. |